Summary:
Kinnate Biopharma is recruiting patients who have been diagnosed with BRAF mutation-positive cancers or NRAS mutation-positive melanomas to participate in a study. Patients must have a metastatic cancer (the cancer has spread from where it started) or advanced stage solid tumor. Please click the link below to learn more!